BIAL - PORTELA & CA, S.A. Patent applications |
Patent application number | Title | Published |
20160051560 | TREATMENTS INVOLVING ESLICARBAZEPINE OR ESLICARBAZEPINE ACETATE - The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 in a human patient. | 02-25-2016 |
20140350057 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-O-METHYLTRANSFERASE INHIBITOR - There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate. | 11-27-2014 |
20140343043 | Composition - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition. | 11-20-2014 |
20140315821 | TREATMENTS INVOLVING ESLICARBAZEPINE ACETATE OR ESLICARBAZEPINE - The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures. | 10-23-2014 |
20140302152 | GRANULATES COMPRISING ESLICARBAZEPINE ACETATE - The invention relates to a solid pharmaceutical composition, the composition comprising eslicarbazepine acetate and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of granules, and wherein at least 90% of the granules of the composition have a particle size of 90 μm or more, and/or wherein at least 50% of the granules of the composition have a particle size of 250 μm or more. The invention also relates to a process for producing a granular composition. Further, the invention relates to the use of the composition in therapy and, in particular, in the treatment or prevention a disorder selected from epilepsy, neuropathic pain, migraine, fibromyalgia an affective disorders. | 10-09-2014 |
20140288058 | METHODS OF PREPARING PHARMACEUTICAL COMPOSITIONS COMPRISING ESLICARBAZEPINE ACETATE AND METHODS OF USE - The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate. | 09-25-2014 |
20140221668 | Process - The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se. | 08-07-2014 |
20140045900 | ADMINISTRATION REGIME FOR NITROCATECHOLS - A compound of formula (I) where R | 02-13-2014 |
20140024682 | PHARMACEUTICAL COMPOUNDS - This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them. | 01-23-2014 |
20130331416 | DOSAGE REGIMEN FOR COMT INHIBITORS - The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day. | 12-12-2013 |
20130324578 | ADMINISTRATION REGIME FOR NITROCATECHOLS - A compound of formula (I) | 12-05-2013 |
20130190276 | USE OF 5-H-DIBENZ/B,F/AZEPINE-5-CARBOXAMIDE DERIVATIVES IN THE TREATMENT OF NEUROPATHIC PAIN AND NEUROLOGICAL DISORDERS - This invention relates to the use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the manufacture of various medicaments for treating neuropathic pain and for treating neurological disorders which involve both motor impairment and neuropathic pain. | 07-25-2013 |
20130150348 | Composition - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition. | 06-13-2013 |
20130123493 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS - A process for preparing a substitute urea of Formula (II) or Formula (I), or a pharmaceutically acceptable salt or ester thereof, Formula (II): Formula (I): the process comprising the reaction of a carbamate of Formula (II′): or formula (I′): with a primary or secondary amine of the formula: R1R2NH, wherein ring A, and R1, R2, R5, V, W, X, Y and Z are as defined herein. | 05-16-2013 |
20130041146 | Asymmetric Catalytic Reduction of Oxcarbazepine - A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX | 02-14-2013 |
20130040939 | Oral Suspension Formulations of Esclicarbazepine Acetate - An oral suspension formulation comprising eslicarbazepine acetate and a pharmaceutically acceptable liquid vehicle. | 02-14-2013 |
20120214797 | Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia - The use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia. Useful 5H-dibenz/b,f/azepine-5-carboxamide derivatives include compounds of the formula (I): | 08-23-2012 |
20120077973 | Sulphonylated Diphenylethylenediamines, Method for Their Preparation and Use in Transfer Hydrogenation Catalysis - A diamine of formula (I) is described in which A is hydrogen or a saturated or unsaturated C1-C20 alkyl group or an aryl group; B is a substituted or unsubstituted C1-C20 alkyl, cycloalkyl, alkaryl, alkaryl or aryl group or an alkylamino group and at least one of X | 03-29-2012 |
20110301204 | ADMINISTRATION REGIME FOR NITROCATECHOLS - The present invention relates to novel dosage regimens for compounds of formula I: where the substituents are as defined in the specification. | 12-08-2011 |
20110237803 | Process - A process for preparing the S or R enantiomer of a compound of formula A, | 09-29-2011 |
20110166360 | Catalytic Process for Asymmetric Hydrogenation - A process for preparing the S or R enantiomer of a compound of formula A, | 07-07-2011 |
20110112303 | Process - A process for preparing the S or R enantiomer of a compound of formula A, | 05-12-2011 |
20110112301 | CRYSTAL FORMS OF 5-[3-(2,5-DICHLORO-4, 6-DIMETHYL-1-OXY-PYRIDINE-3-YL)[1,2,4] OXADIAZOL-5-YL]-3-NITROBENZENE-1,2-DIOL - This invention relates to novel polymorphs of (HO) | 05-12-2011 |
20100298580 | Process for the Preparation of 2H-Chromene-3-Carbamate Derivatives - Compounds of formula I, V, VI and II, and processes for their preparation, | 11-25-2010 |
20100286219 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders - A method comprising utilizing a compound of formula I: | 11-11-2010 |
20100217009 | Process for Preparing Chroman Derivatives - A process for preparing a compound of formula (22), comprising reducing a compound of formula (21), to produce a compound of formula (23), followed by the hydrogenolysis of the compound of formula 23 in a solvent comprising a C | 08-26-2010 |
20100137390 | 1,3-Dihydroimidazole-2-Thione Derivatives as Inhibitors of Dopamine-Beta-Hydroxylase - Compounds of formula I and a method for their preparation are described, where R | 06-03-2010 |
20100121073 | Process for the Preparation of (R)-5-(2-Aminoethyl)-1-(6,8-Difluorochroman-3-YL)-1,3-Dihydroimidazole-2-- Thione - A process for making (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione and pharmaceutically acceptable salts thereof, and for making intermediates useful in the formation of said compound. | 05-13-2010 |
20100113799 | Process for the Preparation of (R) - 5 - (2-Aminoethyl) -1- (6, 8-Difluorochroman-3-YL) -1,3-Dihydroimidazole-2-Thione - A process for making (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione and pharmaceutically acceptable salts thereof, and for making intermediates useful in the formation of said compound. | 05-06-2010 |
20100093817 | Compounds - This invention relates to new 6,8-difluorochroman-3-yl-1,3-dihydroimidazole-2-thiones, their preparation, and their use as a medicament. | 04-15-2010 |
20100048538 | Therapeutical Uses of Eslicarbazepine - New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions, selected from epilepsy, central and peripheric nervous system disorders, affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neurophatic pain and neuropathic pain-related disorders, sensorimotor disorders, vestibular disorders, and nervous function alterations in degenerative and post-ischemic diseases. Preferably the intractable condition is, at least in part, caused by an overexpression of P-gp or MRP. | 02-25-2010 |
20100036127 | Process - A process for preparing the S or R enantiomer of a compound of formula A, | 02-11-2010 |
20090326274 | Sulphonylated Diphenylethylenediamines, Method for Their Preparation and Use in Transfer Hydrogenation Catalysis - A diamine of formula (I) is described in which A is hydrogen or a saturated or unsaturated C1-C20 alkyl group or an aryl group; B is a substituted or unsubstituted C1-C20 alkyl, cycloalkyl, alkaryl, alkaryl or aryl group or an alkylamino group and at least one of X | 12-31-2009 |
20090110722 | Composition - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition. | 04-30-2009 |